This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas

Inclusion Criteria

• Participants must be >=12 months and 6 months and = 50% for participants >16 years of age and Lansky >=50 for participants less than or equal to ( =50% radiation of pelvis; At least 42 days must have elapsed if other substantial bone marrow (BM) radiation.
• Stem Cell Infusion without TBI: No evidence of active graft versus host disease and at least 84 days must have elapsed after transplant or stem cell infusion.
• Adequate Bone Marrow Function Defined as:
• Peripheral absolute neutrophil count (ANC) >=1000 per cubic millimeter (/mm^3).
• Platelet count >=100, 000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment).
• Hemoglobin (Hb) at least 8 gram per deciliter (g/dL) at baseline (blood transfusions are allowed during the screening period to correct Hb values less than 8 g/dL).

All participants enrolled on the study must be evaluable for hematologic toxicity.

• Adequate Renal Function Defined as:
• Creatinine clearance or radioisotope glomerular filtration rate (GFR) >=70 milliliter per minute (ml/min) per (/) 1.73 square meter (m^2) or
• A serum creatinine milligram per deciliter (mg/dL) based on age/gender as follows:
• 6 months to =16 years: male, 1.7; female, 1.4

The threshold creatinine values were derived from the Schwartz formula for estimating GFR (Schwartz et al., 1985) utilizing child length and stature data published by the Centers for Disease Control and Prevention (CDC).

• Adequate Liver Function Defined as:
• Bilirubin (sum of conjugated + unconjugated) = 2 g/dL
• Adequate Cardiac Function Defined as:
• Shortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by gated radionuclide study
• Corrected QT interval (QTc) <= 480 millisecond (msec) Note: Participants with Grade 1 prolonged QTc (450-480 msec) at the time of study enrollment should have correctable causes of prolonged QTc addressed if possible (that is, electrolytes, medications).
• All participants and/or their participants or legally authorized representatives must sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines. Participants must be willing to comply with all aspects of the protocol.
• Participants with known human immunodeficiency virus (HIV) who have CD4+ T cell counts greater than or equal to 500 cells/m^3 and who do not require antiretroviral therapy are eligible.

Exclusion Criteria

• Pregnant or breast-feeding women will not be entered on this study due to risks of fetal and teratogenic adverse events as seen in animal studies. Pregnancy tests must be obtained in girls who are post-menarchal. Males or females of reproductive potential may not participate unless they have agreed to use an effective double barrier contraceptive method for the entire period in which they are receiving protocol therapy and up to 6 months after treatment.
• Concomitant Medications
• Participants receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible.
• Participants who are currently receiving another investigational drug are not eligible.
• Participants who are currently receiving other anticancer agents are not eligible.
• Participants who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial.
• Participants who are receiving drugs that prolong the QTc are not eligible.
• Participants who have received prior therapy with eribulin mesylate are not eligible.
• Participants with hypersensitivity to excipients of the study drug are not eligible. The excipients are ethanol, hydrochloric acid, sodium hydroxide and water for injection.
• Participants who have a prior history of viral hepatitis (B or C) as demonstrated by positive serology (presence of antigens) or have an uncontrolled inf